Evidence map›Paper›PMID 33782102›Full record

ArticleeNeuro

HIV-1 Tat and Morphine Differentially Disrupt Pyramidal Cell Structure and Function and Spatial Learning in Hippocampal Area CA1: Continuous versus Interrupted Morphine Exposure.

William D Marks, Jason J Paris, Aaron J Barbour, Jean Moon, Valerie J Carpenter, Virginia D McLane, Arianna R S Lark, Sara R Nass, Jingli Zhang, Viktor Yarotskyy and 3 more

Open access · goldAbstract read
In one paragraph

Article in eNeuro. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

William D MarksDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298-0613.ORCID 0000-0002-7388-5394
Jason J ParisDepartment of BioMolecular Sciences, University of Mississippi, School of Pharmacy, University, MS 38677-1848.
Aaron J BarbourDepartment of Anatomy and Neurobiology, Virginia Commonwealth University, Richmond, VA 23298-0709.
Jean MoonDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298-0613.
Valerie J CarpenterDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298-0613.
Virginia D McLaneDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298-0613.
Arianna R S LarkDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298-0613.
Sara R NassDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298-0613.
Jingli ZhangDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298-0613.
Viktor YarotskyyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298-0613.
A Rory McQuistonDepartment of Anatomy and Neurobiology, Virginia Commonwealth University, Richmond, VA 23298-0709.
Pamela E KnappDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298-0613.
Kurt F HauserDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298-0613 kurt.hauser@vcuhealth.org.ORCID 0000-0001-7886-0332
Virginia Commonwealth University · USUniversity of Mississippi · US

Funding

TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Sidney S Negus · 2014 to 2026
$13.8M
Training in Alzheimer’s and Age-Related Neurodegenerative DiseasesT32AG000255 · NIA · UNIVERSITY OF PENNSYLVANIA · PI ALICE S CHEN-PLOTKIN, VIRGINIA M LEE · 1997 to 2026
$12.5M
MOR and CCR5 interactive signaling mediates opiate and HIV-driven synaptodendritic injuryR01DA034231 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F, KNAPP, PAMELA E · 2013 to 2023
$5.4M
Mechanisms of Opiate Drug-HIV-Induced NeurodegenerationR01DA018633 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F · 2005 to 2021
$4.4M
HIV opiate interactions in white matter pathologyR01DA044939 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F, KNAPP, PAMELA E · 2017 to 2021
$2.7M
Selective vulnerability of discrete neural circuits in the striatum to HIV-opiate comorbidityR01DA045588 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F · 2018 to 2022
$2.0M
Cells, synapses, and networks contributing to synchrony in the CNSR01MH107507 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI MCQUISTON, ADAM RORY · 2016 to 2020
$1.9M
Neuron-Glia Mechanisms & Interactions Underlying Opioid Abuse-HIV-1 ComorbidityK02DA027374 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F · 2009 to 2018
$1.3M
Opiate abuse and sex steroids influence neuroAIDS pathologyR00DA039791 · NIDA · UNIVERSITY OF MISSISSIPPI · PI PARIS, JASON RICHARD · 2017 to 2019
$734k
HIV and opiate interactions in behavioral and anterior cingulate cortex synaptic dysfunctionF32DA053163 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NASS, SARA · 2021 to 2022
$140k
Opiate and HIV-induced neuropathogenesis in hippocampus: impact on excitatory/inhibitory dysregulationF32DA047193 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI MCLANE, VIRGINIA DIANE · 2018 to 2019
$123k
NIA NIH HHS T32 AG000255NIDA NIH HHS F31 DA047195NIDA NIH HHS F32 DA047193NIDA NIH HHS F32 DA053163NIDA NIH HHS K02 DA027374NIDA NIH HHS P30 DA033934NIDA NIH HHS R00 DA039791NIDA NIH HHS R01 DA018633NIDA NIH HHS R01 DA034231NIDA NIH HHS R01 DA044939NIDA NIH HHS R01 DA045588NIDA NIH HHS T32 DA007027NIMH NIH HHS R01 MH107507
6 · The paper itself

Abstract

About half the people infected with human immunodeficiency virus (HIV) have neurocognitive deficits that often include memory impairment and hippocampal deficits, which can be exacerbated by opioid abuse. To explore the effects of opioids and HIV on hippocampal CA1 pyramidal neuron structure and function, we induced HIV-1 transactivator of transcription (Tat) expression in transgenic mice for 14 d and co-administered time-release morphine or vehicle subcutaneous implants during the final 5 d (days 9-14) to establish steady-state morphine levels. Morphine was withheld from some

Indexed as

HIV-1CA1 Region, HippocampalHippocampusMorphinePyramidal CellsSpatial Learningtat Gene Products, Human Immunodeficiency VirusTrans-ActivatorsMorphinetat Gene Products, Human Immunodeficiency VirusTrans-Activatorsdrug abusehippocampal CA1 pyramidal neuronslearning and memoryneuro-acquired human immunodeficiency syndrome (neuroHIV)neuroadaptation to opioid exposuresynaptodendritic degeneration and dysfunction

Identifiers

PMID33782102
PMCPMC8146490
OpenAlexW3139771604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.